albumin - publications

Predict more albumin - ligand interactions now!


1. J Int Med Res. 2012;40(2):798-803.

Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2
diabetes patients with microalbuminuria.

Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Inoue H, Yamagishi SI.

Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central
General Hospital, Chiba, Japan.

OBJECTIVE: This study investigated the effects of ezetimibe, an inhibitor of
intestinal cholesterol absorption, on early phase diabetic nephropathy.
METHODS: A total of 32 hypercholesterolaemic type 2 diabetes patients with
microalbuminuria, defined as a urinary albumin excretion (UAE) 30 but < 300 mg/g
creatinine, were enrolled. Various clinical and laboratory parameters were
determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe.
RESULTS: Ezetimibe treatment significantly decreased glycated haemoglobin
(HbA(1c)), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE,
and significantly increased high-density lipoprotein-cholesterol and albumin. It
also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but
this difference was not statistically significant. Univariate analyses showed a
correlation between UAE and body mass index, systolic and diastolic blood
pressures, HbA(1c), LDL-C, estimated glomerular filtration rate (inverse),
creatinine and MCP-1. Since these parameters may be closely correlated with each
other, multiple stepwise regression analysis was performed and demonstrated that
HbA(1c) and MCP-1 were independent determinants of UAE.
CONCLUSIONS: Ezetimibe may be a promising therapeutic strategy for improving
albumin excretion, partly through its anti-inflammatory properties, and for
reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with
microalbuminuria.

PMID: 22613445 [PubMed - in process]